Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03601923 · ClinicalTrials.gov registry record · Phase 2

Niraparib in Patients With Pancreatic Cancer

A Phase 2 study of Pancreatic Cancer, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
Phase 2
Development phase
32
Enrollment target
3
Study locations

NCT03601923: Active Phase 2 study of Pancreatic Cancer, sponsored by Dana-Farber Cancer Institute.

NCT03601923 is a Phase 2 study of Pancreatic Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 32 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03601923, a Phase 2 study of Pancreatic Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
32 participants
Enrollment target
3
Study locations

Study Summary

This research study is studying an investigational therapy as a possible treatment for pancreatic cancer. The drugs involved in this study are: -Niraparib

Primary Outcome

Progression-free survival is defined as the time from registration to documented disease progression or death from any cause, whichever occurs first. Subjects who have not experienced an event of interest by the time of analysis will be censored at the date of the last disease assessment without progression.

Conditions Studied

Pancreatic Cancer

Interventions

  • DRUG Niraparib

Study Locations (3)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston
  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2018-08-22
Est. Completion 2026-02-28
Phase Phase 2
Dana-Farber Cancer Institute

781 total trials

What the registry record for NCT03601923 still lists

NCT03601923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (92% lower).

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Niraparib is the first listed.

NCT03601923 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03601923 about?

NCT03601923 is a clinical study titled "Niraparib in Patients With Pancreatic Cancer". This research study is studying an investigational therapy as a possible treatment for pancreatic cancer. The drugs involved in this study are: -Niraparib

What is the current status of trial NCT03601923?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2018-08-22. Estimated completion is 2026-02-28.

What conditions does trial NCT03601923 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT03601923?

The interventions under investigation include: Niraparib (DRUG).

Who is sponsoring clinical trial NCT03601923?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03601923 being conducted?

This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03601923's enrollment target sits among peer trials

32 185th of 278 higher than 91 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03601923, the US trial registry maintained by the National Library of Medicine. NCT03601923 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.